Parker Acquires SciLog to Strengthen Single-use System Capability
News Aug 24, 2012
Parker Hannifin Corporation has announced the acquisition of SciLog Inc, a provider of unique and proprietary single-use technologies and systems for the biopharmaceutical market to support their on-going development as a key supplier to the growing single-use market.
The acquisition will allow Parker to deliver an enhanced bioprocessing portfolio combining filtration and separation expertise, disposable bag systems and automated single-use solutions.
SciLog will be integrated into Parker's Process Filtration Division, which provides high-purity filtration and separation solutions coupled with disposable bags and tubing assemblies for applications such as cell culture media and buffer preparation, product stream filtration and sterile fill finish.
Parker's offering to customers will be enhanced through the addition of SciLog's patented sensor technology for process monitoring and control coupled with unique automation technology from lab to production scale in upstream and downstream processing.
"The addition of SciLog perfectly complements our existing core strengths in filtration and disposable assemblies for the biopharmaceutical market," said Dr Mike Brailsford, General Manager at Parker's Process Filtration Division.
Dr Brailsford continued, "Our customers will now benefit from complete, turnkey solutions that enhance productivity, increase cost-effectiveness and facilitate processing units of operation such as buffer / media prep, virus inactivation etc."
"Today SciLog becomes a global business," said Juliette Schick, CEO and President of SciLog, "With this acquisition SciLog now has a platform in Parker to access global markets, distribution channels and resources to maximize SciLog's single-use product offerings and patent positions."
Parker's expanded capabilities in the biopharmaceutical market will be delivered globally through an extensive and growing global technical support network coupled with customer support centres in over 50 countries.
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018
2nd International Conference on Food Science and Bioprocess Technology
Oct 01 - Oct 03, 2018
3rd Annual Bioprocessing of Advanced Cellular Therapies
May 29 - May 30, 2018